Oocyte vitrification for preserving fertility in patients with endometriosis: first observational cohort study… and many unresolved questions. Letter to the Editor

Raad, J.; Sonigo, Charlotte; Tran, Chloé; Sifer, C.; Durnerin, Isabelle Cédrin; Grynberg, Michaël

doi:10.1016/j.ejogrb.2017.12.001

Cited by 31 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this specific setting, we report the largest cohort (n = 108) to assess FP outcome for women with endometriosis. In 2018, Raad et al published a retrospective cohort study of 62 women with endometriosis [20]. Forty-nine patients completed at least one cycle with similar stimulation parameters as in our study (mean stimulation duration: 11.1 (±2.7) days; mean dose of gonadotropin used: 3634 (±1656) IU).…”

Section: Discussionsupporting

confidence: 59%

Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols

et al. 2020

View full text Add to dashboard Cite

Background: PPOS protocols, initially described for FP in women with cancer, have many advantages compared to antagonist protocols. PPOS protocols were not evaluated for women with endometriosis. The objective of the study was to describe fertility preservation outcomes in women with endometriosis and to compare an antagonist protocol with a Progestin-Primed Ovarian Stimulation (PPOS) protocol. Method: We conducted a prospective cohort study associated with a cost-effectiveness analysis in a tertiary-care university hospital. The measured outcomes included the numbers of retrieved and vitrified oocytes, and direct medical costs. In the whole population, unique and multiple linear regressions analysis were performed to search for a correlation between individual characteristics and the number of retrieved oocyte. Results: We included 108 women with endometriosis who had a single stimulation cycle performed with either an antagonist or a PPOS protocol. Overall, 8.1 ± 6.6 oocytes were retrieved and 6.4 ± 5.6 oocytes vitrified per patient. In the multiple regression model, age (p = 0.001), prior ovarian surgery (p = 0.035), and anti-Mullerian hormone level (p = 0.001) were associated with the number of retrieved oocytes. Fifty-four women were stimulated with an antagonist protocol, and 54 with a PPOS protocol. A mean of 7.9 ± 7.4 oocytes were retrieved in the antagonist group and 8.2 ± 5.6 in the PPOS group (p = 0.78). A mean of 6.4 ± 6.4 oocytes were vitrified in the antagonist group and 6.4 ± 4.7 in the PPOS group (p = 1). In the cost-effectiveness analysis, the PPOS protocol was strongly dominant over the antagonist protocol. Conclusion: Fertility preservation procedures are feasible and effective for patients affected by endometriosis. Antagonist and PPOS protocols were associated with similar results but the medico-economic analysis was in favor of PPOS protocols.

show abstract

Section: Discussionsupporting

confidence: 59%

Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, additional action should be proposed, such as oral contraceptives, to reduce the risk of recurrence of endometriosis . The benefits of fertility preservation should be carefully evaluated according to the severity of the disease (bilateral or unilateral), the type of surgery previously performed, recurrence, and ovarian or peritoneal involvement . As emergency fertility preservation is not mandatory, the first option is oocyte/embryo vitrification after COS.…”

Section: Gynecological Pathologiesmentioning

confidence: 99%

“…56 The benefits of fertility preservation should be carefully evaluated according to the severity of the disease (bilateral or unilateral), the type of surgery previously performed, recurrence, and ovarian or peritoneal involvement. 57,58 As emergency fertility preservation is not mandatory, the first option is oocyte/embryo vitrification after COS. However, the efficiency of the procedure is reduced in women who underwent previous endometrial surgery.…”

Section: Gynecolog Ic Al Patholog Ie Smentioning

confidence: 99%

Challenges of fertility preservation in non‐oncological diseases

Condorelli

Demeestere

2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Clinicians should provide fertility counseling to all patients receiving gonadotoxic treatment. International scientific societies have mainly focused on oncological patients, and fewer efforts have been made to apply these recommendations to women diagnosed with benign disease (eg benign hematological diseases, autoimmune diseases, and gynecological or genetic disorders). However, these indications account for 8%‐13% of the demand for fertility preservation. The risk of premature ovarian failure due to treatment, or to the disease itself, can be considered fairly high for many young women. Counseling and adequate management of these women require particular attention due to the severe health conditions that are associated with some of these diseases. In this review, we address specific issues related to providing adequate fertility counseling and management for women who have been diagnosed with the major non‐oncological indications, based on the literature and on our clinical experience.

show abstract

“…In recent years, the incidence rate of EM has been as high as 10–15%, showing an increasing trend (2). Although EM is a kind of benign tumor, its invasive feature and capacity are similar to those of malignant tumors, so it is difficult to cure.…”

Section: Introductionmentioning

confidence: 99%

Expression and significance of autophagy genes LC3, Beclin1 and MMP-2 in endometriosis

Sui

Sun

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Expression of autophagy-related proteins, microtubule-associated protein light chain 3 (LC3) and Beclin1, and matrix metalloproteinase-2 (MMP-2) was investigated in serum and peritoneal fluid of patients with endometriosis (EM). The messenger ribonucleic acid (mRNA) expression levels of MMP-2, LC3 and Beclin1 in endometrial tissues of EM patients and correlation of these genes with EM and their significance were evaluated. The serum, peritoneal fluid and endometrial tissues of 84 patients treated in The First Affiliated Hospital of Qiqihar Medical University (Qiqihar, China) from March 2016 to March 2017 were collected. The serum, peritoneal fluid and endometrial tissues of 42 EM patients were used as the experimental group, while those of 42 non-EM patients were used as the control group. The levels of LC3, Beclin1 and MMP-2 in serum and peritoneal fluid of EM patients and non-EM patients were quantitatively detected via enzyme-linked immunosorbent assay (ELISA), followed by comparative analysis based on data in both groups. In addition, mRNA expression of LC3, Beclin1 and MMP-2 in the endometrium in both groups were detected via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and differences in expression of these genes between the groups were analyzed and evaluated. Correlation of LC3, Beclin1 and MMP-2 with EM was explored. Results of ELISA showed that levels of LC3 and Beclin1 in the EM group were significantly lower than those in the control group, while levels of MMP-2 in serum and peritoneal fluid of the EM group were significantly higher than those in the control group (P<0.05). Results of RT-qPCR revealed that mRNA expression of LC3 and Beclin1 in the endometrium of patients in the EM group were obviously decreased compared with those in the control group, while the expression of MMP-2 was high, and differences in expression were statistically significant (P<0.05). The expression of MMP-2 is high, and expression of LC3 and Beclin1 is low in serum, peritoneal fluid and endometrium of EM patients, and investigating the expression of MMP-2, LC3 and Beclin1 in EM is helpful to further clarify the pathogenesis of EM, and guide the clinical diagnosis and treatment.

show abstract

Oocyte vitrification for preserving fertility in patients with endometriosis: first observational cohort study… and many unresolved questions. Letter to the Editor

Cited by 31 publications

References 5 publications

Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols

Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols

Challenges of fertility preservation in non‐oncological diseases

Expression and significance of autophagy genes LC3, Beclin1 and MMP-2 in endometriosis

Contact Info

Product

Resources

About